Tovophyllin A 是一种具有口服活性的呫吨酮类化合物,可激活 Akt/GSK3β 信号通路从而对帕金森病发挥神经保护作用,通过激活 Nrf2 对肝损伤小鼠模型发挥保护作用,对急性肺损伤小鼠具有保护性抗炎活性,可抑制 NF-κB 的活化及后续促炎细胞因子的释放,减少凋亡细胞凋亡 (Apoptosis),具有抗疟原虫活性,并对肺上皮癌细胞和乳腺癌细胞具有细胞毒性活性,因此可用于帕金森病、肝损伤、急性肺损伤、肺上皮癌以及乳腺癌的相关研究。
产品编号: MS-W57929 CAS No.: 40738-44-1 分子式: C28H30O6 分子量: 462.53
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

Tovophyllin A 是一种具有口服活性的呫吨酮类化合物,可激活 Akt/GSK3β 信号通路从而对帕金森病发挥神经保护作用,通过激活 Nrf2 对肝损伤小鼠模型发挥保护作用,对急性肺损伤小鼠具有保护性抗炎活性,可抑制 NF-κB 的活化及后续促炎细胞因子的释放,减少凋亡细胞凋亡 (Apoptosis),具有抗疟原虫活性,并对肺上皮癌细胞和乳腺癌细胞具有细胞毒性活性,因此可用于帕金森病、肝损伤、急性肺损伤、肺上皮癌以及乳腺癌的相关研究。

生物实验数据

生物活性 Tovophyllin A is an orally active xanthone compound that exerts neuroprotective effects against Parkinson's disease by activating the Akt/GSK3β signaling pathway, protects against liver injury in mouse models by activating Nrf2, exhibits protective anti-inflammatory activity in mice with acute lung injury, inhibits NF-κB activation and subsequent release of pro-inflammatory cytokines, reduces apoptotic cell apoptosis (Apoptosis), possesses antiplasmodial activity, and shows cytotoxic activity against lung epithelial cancer cells and breast cancer cells, and can therefore be used in research related to Parkinson's disease, liver injury, acute lung injury, lung epithelial cancer, and breast cancer.
体外研究
(In Vitro)

Tovophyllin A (0.01-20 μM; 24 h) 可保护原代皮质神经元免受 MPP+ 和 paraquat (PQ) 诱导的神经细胞毒性,在联合处理 24 h 后,浓度 ≥0.1 μM 时对 MPP+ 模型、浓度 ≥1 μM 时对 PQ 模型的细胞活力均有显著提升。
Tovophyllin A (serial twofold dilutions starting at 200 μM; 48 h) 抑制 A549 人肺腺癌细胞和 MCF7 乳腺癌细胞的增殖,其 IC50 分别为 2.2 μM 和 6.1 μM。

Cell Cytotoxicity Assay

Cell Line: A549 (epithelial lung carcinoma), MCF7 (breast carcinoma)
Concentration: Serial twofold dilutions starting at 200 μM
Incubation Time: 48 h
Result: Exhibited cytotoxic activity against A549 cells with an IC50 of 2.2 μM.
Exhibited cytotoxic activity against MCF7 cells with an IC50 of 6.1 μM.
体内研究
(In Vivo)

Tovophyllin A (5 mg/kg; single pre-treatment dose) 可通过恢复运动功能、保留黑质致密部 (SNc) 中的多巴胺能神经元以及激活 Akt/GSK3β 促存活信号通路,缓解雄性 C57BL/6 小鼠中 MPTP (MS-O89430) 诱导的帕金森病。
Tovophyllin A (50-100 mg/kg; p.o.; once daily; 5 days) 可剂量依赖性地保护雄性 BALB/c 小鼠免受 Acetaminophen (MS-H20928) 诱导的急性肝损伤,其中 100 mg/kg 剂量可几乎完全逆转肝坏死、氧化应激、炎症介质升高的情况,并可强效激活 Nrf2 细胞保护通路。
Tovophyllin A (50-100 mg/kg; p.o.; daily; 5 days prior to LPS challenge) 可呈剂量依赖性改善雄性 BALB/c 小鼠中 LPS (MS-X54539) 诱导的急性肺损伤。

Animal Model: C57BL/6 (male, 8-10 weeks old, 25-28 g, MPTP-induced Parkinson's disease)
Dosage: 5 mg/kg
Administration: single pre-treatment dose
Result: Increased total distance traveled in the open field test to levels comparable to control mice.
Increased latency to fall in the rotarod test to levels comparable to control mice.
Alleviated MPTP-induced reductions in tyrosine hydroxylase (TH) protein levels in the midbrain, and striatum.
Increased the number of TH-positive dopaminergic neurons in the substantia nigra pars compacta (SNc).
Reversed MPTP-induced decreases in the ratio of phosphorylated Akt (Ser473) to total Akt in the midbrain, and striatum.
Reversed MPTP-induced decreases in phosphorylated GSK3β (Ser9) levels in the midbrain, and striatum.
Animal Model: BALB/c (male, 20-30 g, acetaminophen-induced acute liver injury)
Dosage: 50 mg/kg; 100 mg/kg
Administration: p.o.; once daily; 5 days
Result: Reduced the elevated serum alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and lactate dehydrogenase levels induced by acetaminophen.
Reduced the elevated liver necrosis score and myeloperoxidase activity induced by acetaminophen.
Reduced the elevated liver malondialdehyde, 4-hydroxynonenal, and nitrite/nitrate levels induced by acetaminophen, while increasing the levels of superoxide dismutase, catalase, reduced glutathione, and total antioxidant capacity in the liver.
Increased the relative mRNA expression levels of Nrf2, NQO1, GCLm, GCLc, and HO-1 in the liver.
Increased the proportion of Nrf2-immunopositive and HO-1-immunopositive cells in the liver.
Reduced the elevated liver NF-κB levels induced by acetaminophen and decreases the proportion of NF-κB-immunopositive cells.
Reduced the elevated liver TNF-α, IL-1β, and IL-6 levels induced by acetaminophen.
Animal Model: BALB/c albino mice (male, 20-25 g, LPS-induced acute lung injury)
Dosage: 50 mg/kg; 100 mg/kg
Administration: p.o.; daily; 5 days prior to LPS challenge
Result: Significantly reduced LPS-induced lung wet/dry ratio (W/D), total protein content in bronchoalveolar lavage fluid (BALF), and BALF lactate dehydrogenase (LDH) activity.
Inhibited LPS-induced total inflammatory cell count and differential inflammatory cell count (neutrophils, macrophages, lymphocytes) in BALF.
Decreased malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE) levels in lung tissue, and increased superoxide dismutase (SOD) and reduced glutathione (GSH) levels in lung tissue.
Attenuated LPS-induced increases in lung tissue NF-κB levels and percentage of immunopositive cells, as well as decreases in lung tissue TNF-α and IL-6 levels and percentage of immunopositive cells, and decreases in lung tissue IL-1β levels.
Improved LPS-induced pathological damage in lung tissue.

化学信息

分子量 462.53
分子式 C28H30O6
CAS No. 40738-44-1

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础